Trastuzumab deruxtecan
Anti-HER2 antibody-drug conjugate
An antibody-drug conjugate that carries a cytotoxic payload to cells expressing HER2; also discussed in HER2-low groups.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
- Generic name
- fam-trastuzumab deruxtecan-nxki
- Marketed brand names
- Enhertu
- Other names
- T-DXd, DS-8201
- Route
- Intravenous infusion
- Drug class
- Anti-HER2 antibody-drug conjugate
Registration status
Registration status and availability in Indonesia must be confirmed directly with the health facility or authorized distributor. This page is not a source of marketing approval status.
Not a marketing-authorisation source
TanyaKanker does not state a drug's marketing approval status in Indonesia. Confirm official status only through a healthcare facility, BPOM, or an authorised distributor.
Access considerations
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
What needs verification
- Most recent HER2 score and whether the assessment was performed on a recent sample.
- History of pulmonary disorders, because monitoring breathing is an important part.
- Indications applicable in the country where the drug is used.
- Availability of infusion facilities and regular monitoring.
Related
Cancer types
Related markers
Treatment categories
Sources
- NCI Drug Dictionary(lembaga)
Studies related to this drug marker
NCT06452277Phase 3Immunotherapy
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Lung Cancer | biomarker: HER2 | Immunotherapy, Chemotherapy
United States, Argentina, Australia +33279 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker HER2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06452277Not verified
NCT07195695Phase 3Combination regimen
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Lung Cancer | biomarker: HER2 | Immunotherapy, Targeted therapy
United States, Argentina, Australia +25202 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker HER2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07195695Not verified
NCT06324357Phase 1 / Phase 2Targeted therapy
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Stomach Cancer | biomarker: HER2 | Targeted therapy
United States, Belgium, China +7103 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker HER2, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06324357Not verified
NCT06123338Phase 2Combination regimen
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Stomach Cancer | biomarker: HER2 | Immunotherapy, Targeted therapy, Chemotherapy
United States10 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker HER2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06123338Not verified
Request cost and access questions
We prepare cost and availability questions that need direct confirmation from a facility.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- HER2
Biomarker
Reason: Targets this marker
- Chemotherapy
Treatment category
Reason: Uses this drug
- Targeted therapy
Treatment category
Reason: Uses this drug
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Clinical trial
Reason: Uses this drug
- Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Clinical trial
Reason: Uses this drug
- Gastric cancer after chemotherapy no longer gives results
Decision situation
Reason: Related to this page
To check
- Cost and access questions
Tool
Reason: Prepare questions to ask a facility
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.